Press Release
| Life Technologies Introduces New Real-Time PCR System |
Usability and Performance Enhancements Promote New Era of Lab Productivity CARLSBAD, Calif., Apr 19, 2010 (BUSINESS WIRE) --Life Technologies Corporation (NASDAQ:LIFE) today announced the expansion of its industry-leading family of real-time PCR systems with the introduction of a new high-productivity instrument. The Applied Biosystems ViiA(TM) 7 Real-Time PCR System seamlessly integrates a variety of quantitative PCR (qPCR) and genotyping applications, enabling researchers to enter a new era of lab productivity. The system offers a number of performance and usability enhancements that are expected to advance the understanding of molecular biology in the pharmaceutical discovery and clinical research markets. Real-time PCR is a common laboratory method that measures PCR amplification as it occurs, cycle-by-cycle, allowing quantitative measurements to be made in the highly reproducible exponential phase of PCR. This enables extremely accurate and precise quantification of nucleic acids over a large dynamic range compared to traditional techniques. Since the introduction of the first real-time PCR instrument by Applied Biosystems 14 years ago, researchers have increasingly relied on applications of real-time PCR to gain a better understanding of the molecular basis of disease. The ViiA 7 Real-Time PCR System has been designed to improve researcher productivity for research that includes how gene expression changes in response to pharmacological agents, and how genetic variation influences response to treatments for disease. The system optimizes and simplifies a host of real-time PCR applications; all integrated and easily accessible from a touch screen. A patent-pending OptiFlex(TM) System within the ViiA 7 System provides the sensitivity to detect a single copy of starting genetic material and offers enhanced multiplexing flexibility. "In the past decade, quantitative real-time PCR has become a cornerstone technology for the life science researcher, allowing scientists around the world to identify molecular markers for disease and precisely measure how changes in activity at the genome level translate to significant molecular outcomes in living systems," said Peter Dansky, President of Molecular Biology Systems for Life Technologies. "By integrating a broad portfolio of real-time PCR applications on a single high-performance platform, the ViiA 7 Real-Time PCR System will vastly increase the productivity of researchers and inspire them to develop novel workflows that lead to an even greater understanding of the molecular basis of health and disease." The ViiA 7 System's software integrates standard real-time PCR applications like nucleic acid quantification, detection of single nucleotide polymorphisms (SNPs), and copy number variation detection with others that include high-resolution melting, protein analysis with proximity ligation technology, and gene expression analysis performed directly from cultured cells without RNA purification. The ViiA 7 System includes usability enhancements that enable efficient and cost-effective research. Through one-touch protocols, researchers can operate the system without a separate computer and monitor runs from remote locations. Automated sample loading enables uninterrupted system operation and eliminates the need for robotic pipetting equipment. The ViiA 7 Real-Time PCR System will be available in June. About Life Technologies Life Technologies Corporation (NASDAQ:LIFE) is a global biotechnology tools company dedicated to improving the human condition. Our systems, consumables and services enable researchers to accelerate scientific exploration, driving to discoveries and developments that make life even better. Life Technologies customers do their work across the biological spectrum, working to advance personalized medicine, regenerative science, molecular diagnostics, agricultural and environmental research, and 21st century forensics. Life Technologies had sales of $3.3 billion in 2009, employs approximately 9,000 people, has a presence in approximately 160 countries, and possesses a rapidly growing intellectual property estate of approximately 3,900 patents and exclusive licenses. Life Technologies was created by the combination of Invitrogen Corporation and Applied Biosystems Inc., and manufactures both in-vitro diagnostic products and research use only-labeled products. For more information on how we are making a difference, please visit us online at http://www.lifetechnologies.com. Follow Life Technologies on Twitter @LIFECorporation and on Facebook. Safe Harbor Statement This press release includes forward-looking statements about our anticipated results that involve risks and uncertainties. Some of the information contained in this press release, including, but not limited to, statements as to industry trends and Life Technologies' plans, objectives, expectations and strategy for its business, contains forward-looking statements that are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Any statements that are not statements of historical fact are forward-looking statements. When used, the words "believe," "plan," "intend," "anticipate," "target," "estimate," "expect" and the like, and/or future tense or conditional constructions ("will," "may," "could," "should," etc.), or similar expressions, identify certain of these forward-looking statements. Important factors which could cause actual results to differ materially from those in the forward-looking statements are detailed in filings made by Life Technologies with the Securities and Exchange Commission. Life Technologies undertakes no obligation to update or revise any such forward-looking statements to reflect subsequent events or circumstances. For Research Use Only. Not for use in diagnostic procedures. Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=6253755&lang=en SOURCE: Life Technologies Corporation Life Technologies |
 |